Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocular Therapeutix, Inc. - Common Stock
(NQ:
OCUL
)
12.15
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ocular Therapeutix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q3 2025 Results with Narrower-Than-Expected Loss
↗
November 04, 2025
OCULAR THERAPEUTIX reported mixed Q3 2025 results, with a slight revenue miss but a narrower-than-expected loss. The company highlighted progress in its AXPAXLI clinical pipeline.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
October 08, 2025
Via
Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
↗
October 01, 2025
Via
Benzinga
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
September 15, 2025
Via
Benzinga
Earnings Scheduled For August 5, 2025
↗
August 05, 2025
Via
Benzinga
What's Next: Ocular Therapeutix's Earnings Preview
↗
August 04, 2025
Via
Benzinga
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
↗
December 03, 2024
Via
Benzinga
OCUL Sales Drop 18%
↗
August 05, 2025
Via
The Motley Fool
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress
↗
August 05, 2025
OCULAR THERAPEUTIX reported mixed Q2 2025 results, missing revenue and EPS estimates. Stock dipped 6% pre-market but gained 28.5% over the past month. Progress in AXPAXLI™ SOL trials for wet AMD...
Via
Chartmill
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
↗
June 24, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 20, 2025
Via
Benzinga
A Peek at Ocular Therapeutix's Future Earnings
↗
November 13, 2024
Via
Benzinga
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock
↗
August 01, 2024
Via
Benzinga
Analyst Expectations For Ocular Therapeutix's Future
↗
May 06, 2025
Via
Benzinga
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
↗
May 05, 2025
Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results.
Via
Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
↗
April 08, 2025
Via
Benzinga
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
April 08, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
↗
March 18, 2025
Via
Benzinga
Why Ocular Therapeutix Was Bumping Higher This Week
↗
March 14, 2025
Via
The Motley Fool
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
↗
March 11, 2025
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales.
Via
Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
March 11, 2025
Via
Benzinga
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
↗
March 03, 2025
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.
Via
Stocktwits
Earnings Scheduled For March 3, 2025
↗
March 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
January 13, 2025
Via
Benzinga
3 Biotech Stocks to Sell in August Before They Crash & Burn
↗
August 06, 2024
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
Via
InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
